12/02/2026
⭐️Funded Meningococcal Vaccines⭐️
Meningococcal disease is caused by the bacterium Neisseria meningitidis. At least 12 groups have been identified, including groups A, B, C, X, Y and W. The pattern of disease caused by each group varies by time and country or geographical areas. In New Zealand over 2014–2017, meningococcal group B caused around two-thirds of meningococcal disease each year, group C almost one-third and groups Y or W the remaining few cases. In 2022, group B was the prominent type causing 80% of group-identified cases, and group Y and group W made up the other cases. Meningococcal group A rarely causes disease in NZ.
For best protection against all meningococcal disease in New Zealand, separate vaccinations against group B disease and groups A, C, W and Y disease are recommended.
⭐️MENQUADFI (ACYW): one dose
⭐️⭐️BEXSERO (Group B disease): 2 doses 8 weeks apart
These are funded for the below group.
Adolescents and young adults aged 13–25 years inclusively who are entering within the next 3 months, or in their first year of living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison
Please read below if your child had meningitis vaccines as a baby (introduced during previous outbreak)
The recommended dose schedule for Bexsero does not change for individuals with a history of immunisation with MeNZB vaccines. Bexsero utilises four antigen components to induce broad protection against meningococcal group B disease and is significantly different to MeNZB that utilised only one of these antigen components.
Please contact reception for a nurse appointment.